Krisztián N.
- Country
- Hungary
- Department
- Urogenitális Tumorok és Klinikai Farmakológiai Osztály, Kemoterápia C
Research Overview
- Phase 3 Randomized Open-label Study of Opevesostat Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer
- A Phase 3 Randomized, Open-label Study of Opevesostat Tosylate Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
Data & Insights
Has run more than one trial at 17 of 118 partner sites.
Specializations
Oncology Focus
The investigator specializes in the treatment of metastatic castration resistant prostate cancer, conducting research into novel therapeutic approaches for advanced stages of the disease.
- Advanced Prostate Cancer Management
- Metastatic Disease Treatment
- Hormone-Resistant Cancer Therapy
Their research encompasses evaluation of innovative treatments for patients who have undergone prior hormonal therapy.
Treatment Innovation
The investigator focuses on comparing emerging therapeutic options with established treatments for prostate cancer, particularly evaluating novel compounds against current standard-of-care medications.
- Comparative Treatment Studies
- Novel Therapeutic Evaluation
- Treatment Sequencing Strategies
Their work includes assessment of treatment efficacy in patients who have received previous therapeutic interventions.
Clinical Outcomes
The investigator's research emphasizes evaluation of survival outcomes and disease progression in advanced prostate cancer patients.
- Progression-Free Survival Assessment
- Overall Survival Analysis
- Treatment Response Evaluation
Their work involves comprehensive assessment of therapeutic effectiveness through established clinical endpoints.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.